Format

Send to

Choose Destination
Sci Transl Med. 2018 May 16;10(441). pii: eaao4680. doi: 10.1126/scitranslmed.aao4680.

Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

Author information

1
Virginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
2
Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
3
Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA.
4
Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA 23298, USA.
5
AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
6
Cancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79430, USA.
7
Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. acfaber@vcu.edu cbenes@mgh.harvard.edu.
8
Virginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA. acfaber@vcu.edu cbenes@mgh.harvard.edu.

Abstract

High-risk neuroblastoma is often distinguished by amplification of MYCN and loss of differentiation potential. We performed high-throughput drug screening of epigenetic-targeted therapies across a large and diverse tumor cell line panel and uncovered the hypersensitivity of neuroblastoma cells to GSK-J4, a small-molecule dual inhibitor of lysine 27 of histone 3 (H3K27) demethylases ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), and histone demethylase Jumonji D3 (JMJD3). Mechanistically, GSK-J4 induced neuroblastoma differentiation and endoplasmic reticulum (ER) stress, with accompanying up-regulation of p53 up-regulated modulator of apoptosis (PUMA) and induction of cell death. Retinoic acid (RA)-resistant neuroblastoma cells were sensitive to GSK-J4. In addition, GSK-J4 was effective at blocking the growth of chemorefractory and patient-derived xenograft models of high-risk neuroblastoma in vivo. Furthermore, GSK-J4 and RA combination increased differentiation and ER stress over GSK-J4 effects and limited the growth of neuroblastomas resistant to either drug alone. In MYCN-amplified neuroblastoma, PUMA induction by GSK-J4 sensitized tumors to the B cell lymphoma 2 (BCL-2) inhibitor venetoclax, demonstrating that epigenetic-targeted therapies and BCL-2 homology domain 3 mimetics can be rationally combined to treat this high-risk subset of neuroblastoma. Therefore, H3K27 demethylation inhibition is a promising therapeutic target to treat high-risk neuroblastoma, and H3K27 demethylation can be part of rational combination therapies to induce robust antineuroblastoma activity.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center